CD44 and breast carcinoma: On purified mammospheres by clonal selection, CD44, the most consistently used biomarker, together with Cd24low, to identify and characterize the breast cancer stem cell (BCSC) phenotype [13], was also measured by cytofluorimetry, indicating that about 90% of the purified stem cells were CD44+ (Figure 1C).